Otis Brawley, M.D., and Matthew Ong, of The Cancer Letter, were on the panel “How precision medicine and immunotherapy are redefining the approach to cancer treatment.”
Are precision medicine and immunotherapy overhyped as cancer treatments, or do they hold such tremendous promise that we are only just starting to see the potential?
That was the overarching question for the panel discussion at Health Journalism 2019, “How precision medicine and immunotherapy are redefining cancer treatment.”
“I do worry that precision medicine and immunotherapy are overhyped,” said Otis W. Brawley, M.D., Bloomberg distinguished professor of oncology and epidemiology at the Bloomberg School of Public Health and John Hopkins Kimmel Cancer Center. Brawley also was the Thursday night speaker at Health Journalism 2019. Continue reading